Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
53.1M
-
Number of holders
-
109
-
Total 13F shares, excl. options
-
48.5M
-
Shares change
-
+2.79M
-
Total reported value, excl. options
-
$292M
-
Value change
-
-$2.81M
-
Put/Call ratio
-
0.27
-
Number of buys
-
65
-
Number of sells
-
-50
-
Price
-
$6.03
Significant Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q2 2024
141 filings reported holding ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share as of Q2 2024.
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) has 109 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.5M shares
of 53.1M outstanding shares and own 91.3% of the company stock.
Largest 10 shareholders include venBio Partners LLC (9.7M shares), FMR LLC (7.81M shares), Vivo Capital, LLC (4.22M shares), Redmile Group, LLC (4.04M shares), Vestal Point Capital, LP (3.6M shares), BlackRock Inc. (2.69M shares), MPM BIOIMPACT LLC (2.18M shares), ORBIMED ADVISORS LLC (1.89M shares), VANGUARD GROUP INC (1.73M shares), and Paradigm Biocapital Advisors LP (1.58M shares).
This table shows the top 109 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.